Morning Briefing
Summaries of health policy coverage from major news organizations
Perspectives: Mark Cuban Cost Plus Drug Co. On The Right Track, But Needs More Work
Mark Cuban, the billionaire 鈥淪hark Tank鈥 celebrity and Dallas Mavericks owner, is getting attention again 鈥 this time for his Mark Cuban Cost Plus Drug Co., which seeks to reduce prescription drug prices for Americans. A new study finds that Medicare could have saved $3.6 billion in 2020 if it had paid Mark Cuban drug prices. (Peter Neumann, Joshua Cohen and Daniel Ollendorf, 7/11)
The brash billionaire and owner of the Dallas Mavericks has launched an online pharmacy with a mission: upending the business model that makes prescription drug manufacturing and distribution reliably profitable. It's a system that often leaves consumers struggling to pay for the drugs they need. (7/10)
After a decade-long wait, the Food and Drug Administration finally issued a proposed rule in late June that would make it easier for pharmaceutical companies to switch products from prescription-only to over-the-counter status while still retaining a prescription version. (Martha Rumore, 7/12)
Drugs containing PFAS and conditions with treatments that introduce the presence of PFAS include, but are not limited to, tachyarrhythmias (flecainide), antidepressants (fluoxetine), nonsteroidal anti-inflammatories (celecoxib), antibiotics (levofloxacin), rheumatoid arthritis therapeutics (leflunomide), cholesterol-lowering agents (atorvastin) and even COVID-19 antivirals such as Paxlovid. (David Clement, 7/10)
When you make the diagnosis of pneumonia, how do you decide if the patient should receive antibiotics? Do you use the clinical symptoms? Chest xray (CXR) results? Other criteria? (Rachel Y. Moon, MD, 7/5)
As the U.S. Congress debates a must-pass bill reauthorizing Food and Drug Administration (FDA) user fees for drug and device companies, the future of the FDA鈥檚 accelerated-approval program has become a focus of policy discussion. (Rachel E. Sachs, J.D., M.P.H., et al, 7/6)